Patents by Inventor Hans Georg Fliri

Hans Georg Fliri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220079139
    Abstract: The present invention provides a cyclosporin analog and use thereof, and in particular relates to a compound and use thereof as a mitochondrial protective agent for storing a donated organ. The compound is a compound of formula 1 or a salt thereof, wherein n is 2-5, and R1 and R2 are independently selected from H or C1-C4 alkyl, wherein R1 and R2 can be linked together to form a C3-C5 heteroalkyl ring.
    Type: Application
    Filed: January 8, 2020
    Publication date: March 17, 2022
    Inventors: Ching Pong Mak, Michael Robert Peel, Hans Georg Fliri, Shengqiang Yu, Li Zeng
  • Publication number: 20180153958
    Abstract: The present invention relates to novel cycloundecadepsipeptide compounds and their analogues which bind and inhibit cyclophilins, have reduced immunosuppressive activity and improved physicochemical properties including water solubility. The present invention further relates to pharmaceutical compositions containing said depsipeptide compounds and their analogues for use in the treatment or prevention of diseases and pathologies which may be ameliorated by the inhibition of cyclophilin activity.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 7, 2018
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, Antonio Kuok Keong Vong
  • Patent number: 9895412
    Abstract: The present invention relates to novel cycloundecadepsipeptide compounds and their analogues which bind and inhibit cyclophilins, have reduced immunosuppressive activity and improved physicochemical properties including water solubility. The present invention further relates to pharmaceutical compositions containing said depsipeptide compounds and their analogues for use in the treatment or prevention of diseases and pathologies which may be ameliorated by the inhibition of cyclophilin activity.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: February 20, 2018
    Assignee: Cypralis Limited
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, Antonio Kuok Keong Vong
  • Patent number: 9670175
    Abstract: Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. The compounds may be of formula (I) wherein R1 is H or an optionally substituted alkyl group or a group of formula (II) and R2 is independently a group according to formula (II) where formula (II) is as defined 10 herein.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: June 6, 2017
    Assignee: NEUROVIVE PHARMACEUTICALS AB
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, David Arthur Scowen, Derek Gregory Batcheller, Kari Henrik Johannes Ehinger, Mats Eskil Elmer, Magnus Joakim Hansson, Karl Fredrik Lennart Sjovall
  • Publication number: 20170007664
    Abstract: The present invention relates to novel cycloundecadepsipeptide compounds and their analogues which bind and inhibit cyclophilins, have reduced immunosuppressive activity and improved physicochemical properties including water solubility. The present invention further relates to pharmaceutical compositions containing said depsipeptide compounds and their analogues for use in the treatment or prevention of diseases and pathologies which may be ameliorated by the inhibition of cyclophilin activity.
    Type: Application
    Filed: June 20, 2016
    Publication date: January 12, 2017
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, Antonio Kuok Keong Vong
  • Patent number: 9382295
    Abstract: The present invention relates to novel cycloundecadepsipeptide compounds and their analoges which bind and inhibit cyclophilins, have reduced immunosuppressive activity and improved physicochemical properties including water solubility. The present invention further relates to pharmaceutical compositions containing said depsipeptide compounds and their analoges for use in the treatment or prevention of diseases and pathologies which may be ameliorated by the inhibition of cyclophilin activity.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: July 5, 2016
    Assignee: Cypralis Limited
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, Antonio Kuok Keong Vong
  • Publication number: 20150259386
    Abstract: The present invention relates to novel cycloundecadepsipeptide compounds and their analogues which bind and inhibit cyclophilins, have reduced immunosuppressive activity and improved physicochemical properties including water solubility. The present invention further relates to pharmaceutical compositions containing said depsipeptide compounds and their analogues for use in the treatment or prevention of diseases and pathologies which may be ameliorated by the inhibition of cyclophilin activity.
    Type: Application
    Filed: October 2, 2013
    Publication date: September 17, 2015
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, Antonio Kuok Keong Vong
  • Publication number: 20150259317
    Abstract: Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. The compounds may be of formula (I) wherein R1 is H or an optionally substituted alkyl group or a group of formula (II) and R2 is independently a group according to formula (II) where formula (II) is as defined 10 herein.
    Type: Application
    Filed: October 4, 2013
    Publication date: September 17, 2015
    Applicant: Mitopharm Ltd
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, David Arthur Scowen, Derek Gregory Batcheller, Karl Henrik Johannes Ehinger, Mats Eskil Elmér, Magnus Joakim Hansson, Karl Fredrik Lennart Sjövall
  • Publication number: 20120264679
    Abstract: This invention relates to cyclosporin derivatives of general formula (I): wherein A, B, R1, R2 and X are as defined in the specification, and pharmaceutical compositions prepared from the same, for use in treatment of hepatitis C virus.
    Type: Application
    Filed: June 20, 2012
    Publication date: October 18, 2012
    Applicant: SCYNEXIS, INC.
    Inventors: Hans Georg Fliri, David Renwick Houck
  • Publication number: 20100167996
    Abstract: This invention relates to cyclosporin derivatives of general formula (I): wherein A, B, R1, R2 and X are as defined in the specification, and pharmaceutical compositions prepared from the same, for use in treatment of hepatitis C virus.
    Type: Application
    Filed: December 21, 2009
    Publication date: July 1, 2010
    Inventors: Hans Georg Fliri, David Renwick Houck
  • Patent number: 7718767
    Abstract: This invention relates to cyclosporin derivatives of general formula (I): wherein A, B, R1, R2 and X are as defined in the specification, and pharmaceutical compositions prepared from the same, for use in treatment of hepatitis C virus.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: May 18, 2010
    Assignee: Scynexis, Inc.
    Inventors: Hans Georg Fliri, David Renwick Houck
  • Patent number: 7196161
    Abstract: This invention relates to cyclosporin derivatives of general formula (I): wherein A, B, R1, R2 and X are as defined in the specification, and pharmaceutical compositions prepared from the same, for use in treatment of hepatitis C virus.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: March 27, 2007
    Assignee: Scynexis Inc.
    Inventors: Hans Georg Fliri, David Renwick Houck